檢視一下 BioNTech SE與上海復星之英文合約與後者之中文官網

20201215：BNT與上海復星的英文合約（沒看見「大中華」）

【縛雞之見】
BNT與上海復星，在20201215的英文合約，如下：

the development and license agreement (the “License Agreement”) between Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.* (上海復星醫藥產業發展有限公司) (“Fosun Pharmaceutical Industrial”) and BioNTech SE (“BioNTech”)

供貨合約簽約主體：BioNTech SE / 上海復星醫藥產業發展有限公司（上海復星子公司）

 

(b) Supply Agreement 供貨協議

The Board further announces that, on 15 December 2020, BioNTech Manufacturing GmbH, a subsidiary of BioNTech (“BioNTech Manufacturing”), Fosun Pharmaceutical Industrial and BioNTech entered into a supply agreement in relation to the supply of the Coronavirus Vaccine Product in Chinese Mainland (the “Supply Agreement”).
供貨協議提供者：BioNTech Manufacturing GmbH（BioNTech子公司），
供貨範圍：中國本土。

Supply of Products 供貨商品
Under the Supply Agreement, subject to the obtaining of the marketing authorisation in Chinese Mainland and the relevant purchase orders having been furnished by Fosun Pharmaceutical Industrial under the Supply Agreement, BioNTech Manufacturing commits to supply no less than 100 million doses of the Coronavirus Vaccine Product for Chinese Mainland in 2021.
供貨範圍：中國本土，與「在本協議下由上海復星所供貨的相關訂單」

Profit Sharing 利益比例
Subject to the terms of the Amendment No. 1, the provisions for the share of profit for the sale of Coronavirus Vaccine Product in Chinese Mainland, Hong Kong and Macau under the License Agreement shall be amended as follows:
利潤比，包括中國本土、香港、澳門

(1) with respect to the Finished Product supplied by BioNTech (and/or its affiliates), Fosun Pharmaceutical Industrial (and/ or its affiliates) and BioNTech (and/or its affiliates) shall be entitled to a share of profit at the rate of 65% and 35% of annual gross profit, respectively; and
BNT與附屬公司提供之「最終商品」，利潤比是，(1)復星：BNT＝65：35，（此時包含港澳，每年年度毛利）。

(2) with respect to Bulk DP supplied by BioNTech (and/ or its affiliates), Fosun Pharmaceutical Industrial (and/or its affiliates) and BioNTech (and/or its affiliates) shall be entitled to a share of profit at the rate of 60% and 40% of annual gross profit, respectively.
BNT提供之大瓶裝產品，復星：BNT＝60：40（每年年度毛利）。

https://www.fosunpharma.com/uploads/2020121684019.pdf

 

但復星的中文網頁，20200315的中文新聞稿，卻說包含台灣。「根據協議，復星醫藥產業負責該疫苗在中國大陸及港澳臺地區（「區域內」）的臨床試驗、上市申請和市場銷售，並承擔相應的成本和費用。」

https://www.fosunpharma.com/zh-tw/news/news-details-3801.html